Featuring: Atique Ahmed, PhD, Priya Kumthekar, MD, GME, Issam Ben-Sahra, PhD, Craig Horbinski, MD, PhD, Maciej Lesniak, MD, Jason Miska, PhD, C. David James, PhD, Roger Stupp, MD
A drug currently used to prevent organ rejection in transplants could also reduce chemotherapy resistance in glioblastoma, according to a Northwestern Medicine study published in Brain.
The drug prevents glioblastoma cells from using molecular plasticity to circumvent chemotherapy, and Northwestern Medicine investigators are currently working to translate these findings to the clinic, according to Atique Ahmed, PhD, associate professor of Neurological Surgery and senior author of the study.
“These cancer cells are very adaptable, and this is one reason why they resist our current therapies,” said Ahmed. “Because we are repurposing an already approved drug, this could speed up the clinical testing.”
Glioblastoma is a particularly deadly brain cancer, and patients usually have a short life expectancy after diagnosis. The current standard of care is surgical resection, radiation and chemotherapy.
Among the most effective chemotherapy drugs for glioblastoma is temozolomide, which corrupts purine molecules in cancer cells. Purine is essential for DNA synthesis, so cells attempting to use this “bad” purine will eventually die. However, glioblastoma cells are extraordinarily adaptable, allowing them to accumulate resistance to the therapy, according to Ahmed.
“They can acquire a different form and shape at the molecular level based on their microenvironment,” Ahmed said. “Once they’ve gained this resistance, the cancers comes back and is often very aggressive.”
In the study, Ahmed and his collaborators analyzed the epigenetic profile of glioblastoma cells being treated with temozolomide, finding that specific genes are modulated during therapy. One gene that is modulated, ARL13B, is known for its role in cilia. In this case, the gene helps cancer cells process their own purine, blocking the tainted purine from harming the cancer cells.
“They make fresh purine and they can avoid the purine damaged by chemotherapy,” Ahmed said.
Inhibiting an ARL13B pathway in experiments forced glioblastoma cells to rely on the damaged purine, and this pathway can be blocked with a previously developed drug: mycophenolate mofetil. An immunosuppressive medication usually used in organ transplants, the drug blocks glioblastoma cells to produce fresh purine and rely on the damaged purine. When combined with chemotherapy in models of glioblastoma, mycophenolate mofetil enhanced the therapeutic efficacy of temozolomide.
The fact that mycophenolate mofetil is already approved should speed translation from bench to bedside, according to Priya Kumthekar, MD, GME, associate professor in the Ken and Ruth Davee Department of Neurology Division of Neuro-Oncology and a co-author of the study.
“Repurposing of drugs, as opposed to new drugs, allows for faster development of its use in any given disease as the safety profile in humans is much better understood,” said Kumthekar, who is also an associate professor of Medicine in the Division of Hematology and Oncology.
This work was supported by the National Institute of Neurological Disorders and Stroke grants 1R01NS096376, R01NS095642 and 1R01NS112856; American Cancer Society grant RSG-16-034-01-DDC,; National Institute of Cancer grant R00CA194192; National Institute of Medicine grants R01GM135587 and R35CA197725, and P50CA221747 SPORE for Translational Approaches to Brain Cancer.
Co-authors of the study include Issam Ben-Sahra, PhD, assistant professor of Biochemistry and Molecular Genetics; Craig Horbinski, MD, PhD, director of Neuropathology in the Department of Pathology; Maciej Lesniak, MD, the chair and Michael J. Marchese Professor of Neurosurgery; Jason Miska, PhD, research assistant professor of Neurological Surgery; C. David James, PhD, the Jean Malnati Miller Professor of Brain Tumor Research and vice chair for research in the Department of Neurological Surgery and Roger Stupp, MD, the Paul C. Bucy Professor of Neurological Surgery, chief of Neuro-Oncology in the Department of Neurology and a professor of Medicine in the Division of Hematology and Oncology.
Ahmed, Kumthekar, Ben-Sahra, Horbinski, James, Lesniak, Miska and Stupp are members of the Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
This article was originally published in the Feinberg School of Medicine News Center on June 10, 2021.
Atique Ahmed, PhD, associate professor of Neurological Surgery.
Priya Kumthekar, MD, GME, associate professor of Neuro-oncology, Hematology and Oncology.
Issam Ben-Sahra, PhD, assistant professor of Biochemistry and Molecular Genetics.
Craig Horbinski, MD, PhD, director of Neuropathology in the Department of Pathology and professor of Experimental Pathology, Neurological Surgery and Pathology.
Maciej Lesniak, MD, chair of Neurological Surgery and the Michael J. Marchese Professor of Neurosurgery.
Jason Miska, PhD, assistant professor of Neurological Surgery.
C. David James, PhD, professor Emeritus of Neurological Surgery.
Roger Stupp, MD, chief of Neuro-oncology in the Department of Neurology, Paul C. Bucy Professor of Neurological Surgery, and serving as co-director of the Lou and Jean Malnati Brain Tumor Institute and associate director for the Lurie Comprehensive Cancer Center.
Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients.